Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Selumetinib for Plexiform Neurofibroma in NF1
NCT06502171Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Aug 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabozantinib and selumetinib in neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN). Started Jun 2026; status: recruiting.
02
Drugs
cabozantinibselumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)
Beyond the preview
Go deeper on NCT06502171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06502171.